title: Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10.
abstract: We analyzed plasma 8OHdG concentrations in 20 individuals enrolled in the Pre-2CARE study before and after treatment with CoQ. Treatment resulted in a mean reduction in 8OHdG of 2.9 ± 2.9 pg/ml for the cohort (p = 0.0003) and 3.0 ± 2.6 pg/ml, for the HD group (p = 0.002). Baseline 8OHdG levels were not different between individuals with HD and controls (19.3 ± 3.2 pg/ml vs. 19.5 ± 4.7 pg/ml, p = 0.87) though baseline CoQ levels were elevated in HD compared with controls (p < 0.001). CoQ treatment reduces plasma 8OHdG and this reduction may serve as a marker of pharmacologic activity of CoQ in HD.
authors: Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. Kevin_biglan@urmc.rochester.edu
authors: K M
authors: KM
authors: Biglan
authors: Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
authors: E R
authors: ER
authors: Dorsey
authors: Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA.
authors: R V V
authors: RV
authors: Evans
authors: Departments of Psychiatry, Neurology, Neuroscience and Pharmacology, Johns Hopkins University, Baltimore, MD, USA.
authors: C A
authors: CA
authors: Ross
authors: Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.
authors: S
authors: S
authors: Hersch
authors: Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA Department of Neurology, Georgetown University, Washington, D.C., USA.
authors: I
authors: I
authors: Shoulson
authors: Boston University School of Medicine, Boston, MA, USA.
authors: W
authors: W
authors: Matson
authors: Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA.
authors: K
authors: K
authors: Kieburtz
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000097:blood; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D014451:Ubiquinone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D015415:Biomarkers; D014451:Ubiquinone; D000080242:8-Hydroxy-2'-Deoxyguanosine; C024989:coenzyme Q10; D003849:Deoxyguanosine
keywords: 8OHdG; Huntington disease; coenzyme Q10; oxidative injury